ferric pyrophosphate citrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5122	1332-96-3

Description:

Molecule

Description

Synonyms:

ferric pyrophosphate citrate
ferric pyrophosphate soluble
sodium ferricitropyrophosphate
soluble ferric pyrophosphate
triferic

Molecular weight: 485.75
Formula: C6H9Fe2NaO13P2
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 120.39
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 23, 2015	FDA	ROCKWELL MEDICAL INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombosis in device	92.57	75.10	12	36	2978	63485996

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombosis in device	265.12	102.99	33	26	3292	34953580

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombosis in device	308.24	93.88	39	59	5403	79738887

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Iron supplement therapy	indication	438911000124105

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
272MG IRON/PACKET	TRIFERIC	ROCKWELL MEDICAL INC	N208551	April 25, 2016	DISCN	FOR SOLUTION	INTRAVENOUS	7857977	Sept. 8, 2027	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
27.2MG IRON/5ML (5.44MG IRON/ML)	TRIFERIC	ROCKWELL MEDICAL INC	N206317	Jan. 23, 2015	DISCN	SOLUTION	INTRAVENOUS	7816404	April 17, 2029	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
272MG IRON/PACKET	TRIFERIC	ROCKWELL MEDICAL INC	N208551	April 25, 2016	DISCN	FOR SOLUTION	INTRAVENOUS	7816404	April 17, 2029	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
6.75MG IRON/4.5ML (1.5MG IRON/ML)	TRIFERIC AVNU	ROCKWELL MEDICAL INC	N212860	March 27, 2020	DISCN	SOLUTION	INTRAVENOUS	7816404	April 17, 2029	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
UBY79OCO9G	UNII
4034821	VANDF
C4018308	UMLSCUI
CHEMBL3833317	ChEMBL_ID
DB13995	DRUGBANK_ID
1607975	RXNORM
232967	MMSL
016429	NDDF
1802359-96-1	SECONDARY_CAS_RN
90465822	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Triferic	HUMAN PRESCRIPTION DRUG LABEL	1	57278-314	SOLUTION	5.44 mg	PARENTERAL	NDA	25 sections
Triferic	HUMAN PRESCRIPTION DRUG LABEL	1	57278-314	SOLUTION	5.44 mg	PARENTERAL	NDA	25 sections
Triferic	HUMAN PRESCRIPTION DRUG LABEL	1	57278-315	POWDER	272 mg	PARENTERAL	NDA	25 sections
Triferic	HUMAN PRESCRIPTION DRUG LABEL	1	57278-315	POWDER	272 mg	PARENTERAL	NDA	25 sections
Triferic AVNU	HUMAN PRESCRIPTION DRUG LABEL	1	57278-318	SOLUTION	1.50 mg	INTRAVENOUS	NDA	24 sections